HK Stock Market Move | CSTONE PHARMA-B (02616) rose more than 5% in early trading. Its CS2009 II Phase clinical trial application has been approved by the US FDA.

CSTONE PHARMA-B (02616) rose more than 5% in early trading, rising 4.74% to HK $6.19 as of the report, with a turnover of HK $26.54 million. In terms of news, Cornerstone Pharmaceuticals announced that the Company's core asset CS2009, used in Phase II clinical trials for advanced solid tumors, has received FDA approval for its IND application. CS2009 (PD-1/VEGF/CTLA-4 triple-specific antibody) for Phase II clinical trials of new drugs for advanced solid tumors received approval from the U.S. Food and Drug Administration (FDA), marking a significant development in the global development of this innovative immunotherapy. The announcement stated that preliminary data from the Phase I clinical study of CS2009 was presented at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting, showing good safety and tolerability, as well as positive anti-tumor activity data. More Phase I and Phase II clinical trial data are expected to be presented at the American Society of Clinical Oncology (ASCO) and ESMO meetings this year.